Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in the Enhance-1 Phase 3 Trial of Ensifentrine in COPD

被引：0

作者：

Sciurba, F. C. ^{[1
]}

Wise, R. A. ^{[2
]}

Rheault, T. ^{[3
]}

Bengtsson, T. ^{[4
]}

Rickard, K. ^{[3
]}

机构：

[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[2] Johns Hopkins Univ, Sch Med, Pulm & Crit Care, Baltimore, MD USA

[3] Verona Pharma Plc, Raleigh, NC USA

[4] Stat Mind AB, Lund, Sweden

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 207卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A5006

引用

页数：2

共 26 条

[1] Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Improves COPD Symptoms and Quality of Life in the Phase 3 Enhance-1 Trial
Sciurba, F. C.
Rheault, T.
Bengtsson, T.
Rickard, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[2] Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function and Reduces Exacerbation Rate and Risk in Phase 3 Enhance-2 Trial
Anzueto, A.
Barjaktarevic, I.
Rheault, T.
Bengtsson, T.
Rickard, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[3] Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in Patients With COPD: Results From Replicate Phase 3 Trials
Sciurba, F. C.
Anzueto, A.
Rheault, T.
Bengtsson, T.
Rickard, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[4] ENSIFENTRINE, A NOVEL DUAL PHOSPHODIESTERASE (PDE) 3 AND 4 INHIBITOR, REDUCES EXACERBATION RATE AND RISK REGARDLESS OF EXACERBATION HISTORY IN POOLED ENHANCE TRIAL ANALYSES
Sciurba, Frank C.
Rheault, Tara
Bengtsson, Thomas
Rickard, Kathleen Ann
CHEST, 2023, 164 (04) : 5003A - 5004A
[5] Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, in Moderate and Severe COPD: Symptoms, Quality of Life and Health Status From the Phase 3 Trial Enhance-2
Rheault, T.
Bengtsson, T.
Rickard, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[6] Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Significantly Reduces Annualized Exacerbations and Delays the Time to First Exacerbation in COPD: Pooled Sub-Group Analyses of Enhance-1 and Enhance-2 Phase 3 Trials
Barjaktarevic, I.
Rheault, T.
Bengtsson, T.
Rickard, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[7] Effect of Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine on Exacerbation Rate and Risk in Patients With Moderate to Severe COPD
Sciurba, Frank C.
Christenson, Stephanie A.
Rheault, Tara
Bengtsson, Thomas
Rickard, Kathleen
Barjaktarevic, Igor Z.
CHEST, 2025, 167 (02) : 425 - 435
[8] UNIQUE DUAL PHOSPHODIESTERASE 3/4 INHIBITOR, ENSIFENTRINE, SIGNIFICANTLY IMPROVES COPD SYMPTOMS INCLUDING DYSPNEA
Rickard, Kathleen
Rheault, Tara
Maurer, Brian
Singh, Dave
CHEST, 2019, 156 (04) : 450A - 451A
[9] Ensifentrine Reduced Healthcare Resource Utilization in Subjects With COPD: Results From Enhance-2, a Phase 3 Trial of Ensifentrine, a Dual PDE3/4 Inhibitor
Barjaktarevic, I.
Rheault, T.
Bengtsson, T.
Rickard, K.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
[10] Ensifentrine Dual phosphodiesterase PDE3/4 inhibitor Treatment of COPD Treatment of cystic fibrosis
Calzetta, L.
Matera, M. Gabriella
Rogliani, P.
Cazzola, M.
DRUGS OF THE FUTURE, 2019, 44 (11) : 845 - 854

← 1 2 3 →